45. Kägi M.K., Veltman H.J., Becker H., Zurbriggen B., Burg G., Wüthrich B.: Neoral (ciclosporin A) in atopicdermatitis: first results with a new galenical formulation. Presented to the Swiss Society for Allergy and Immunology, Lausanne, April 1995. Abstract C2 (o). 46. Kägi M.K., Veltmann H.J., Becker H., Zurbriggen B., Burg G., Wüthrich B.: Sandimmun (ciclosporin A) in atopicdermatitis: first results with a new galenical formulation. Presented to the German Society for Dermatology, Berlin, Germany, April 1995. Abstract P 1.03.30 (o). 47. Wüthrich B., Schindler C., Leuenberger P., Ackermann-Liebrich U. and the SAPALDIA team. Presented by Kägi M.K.: Prevalences of skin prick test positivity, pollinosisand atopic asthma in eight areas of Switzerland. Presented to the Joint International Symposium “New trends in Allergy IV” Hamburg, April 1995. Abstract 2 (o/p). 48. Bächli E., Kägi M.K., Krause M.: Visceral complicationsin varicella infecctions of the adults. Presented to the Swiss Society for Internal Medicine, Montreux, May 1995. Abstract P285 (o). 49. Kägi M.K., Rust C., Veltmann H.J., Zurbriggen B., Burg G., Wüthrich B.: Sandimmun (ciclosporin A) in atopicdermatitis: first results with a neuw galenical formulation. Presented to the European Academy of Allergy and Clinical Immunology, Madrid, Spain, June 1995. Abstract 861 (p). 50. Nestle F.O., NickoloffB.J., Kägi M.K., Bpchner S., Burg G.: Tumorassociated antigen presenting cells in the skin demonstrate a significantly reduced expression of important costimulatory molecules. Presneted tothe Sodiety for Operative and Oncologic Dermatology, Zürich, June 1995. Abstract V29 (o). 51. Kägi M.K., Zurbriggen B., Burg G., Wüthrich B.: Sandimmun (ciclosporin A) in atopic dermatitis: preliminary results with a new galenical formulation. Presented to the Swiss Society for Dermatology and Venerology, Basel, September 1995. Abstract (o+p). 52. Kägi M.K., Kleinhans M., Zurbriggen B., Burg G., Wüthrich B.: Ciclosporin A in atopic dermatitis: preliminary results with a new galenical formulation. Presented to the European Academy for Dermatology and Venerology, Brussels, October 1995. Abstract (o). 53. Kägi M.K., Zurbriggen B., Burg G., Wüthrich B.: Ciclosporin A treatment of atopic dermatitis: monitoring the clinicalactivity with serological parameters. Presented to the Swiss Society for allergy and Immunology, St. Gallen, April 1996. Abstract C2 (p). 54. Kägi M.K.: The leucotriene receptor antagonist montelukast in the treatment atopic dermatitis of the face. Presented to the European Academi for Dermatologie and Venerologie, Geneva, October 2000. Abstract p06-16 (p). Reviews of literature 1. Kägi M.K.: Usefulness ofimmunotherapy in patients with severe summer hayfever uncontrolled by antiallergic drugs. Schweiz. med. Wschr. 1991;121:1591. 2. Kägi M.K.: Preliminary report: complement activation in wasp-sting anaphylaxis. Schweiz. med. Wschr. 1991;121:1591. 3. Kägi M.K.: Eosinophil cationic protein – a new serological marker for atopic dermatitis? Dermatologica Helvetica 1991;7:15. 4. Kägi M.K., Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. Schweiz. med. Wschr. 1992;122:1141. 5. Kägi M.K.: High dose UVA1-therapy in patients with atopic dermatitis. Dermatologica Helvetica 1992;5:16. .
RkJQdWJsaXNoZXIy MjYwOTU=